CLU and melanoma: Among the proteins identified, five were selected for validation by ELISA as potential serum biomarkers of prognosis and disease outcome in the 348 melanoma patients and 100 healthy controls: two apolipoproteins related to inflammatory and immune responses, SAA and CLU; two proteins involved in adhesion, PG and VN and an antimicrobial protein, DCD.